The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).
Sandro Pignata
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Domenica Lorusso
Consultant or Advisory Role - Janssen-Cilag; Roche
Research Funding - PharmaMar
Giovanni Scambia
No relevant relationships to disclose
Daniela Sambataro
No relevant relationships to disclose
Stefano Tamberi
No relevant relationships to disclose
Saverio Cinieri
No relevant relationships to disclose
Anna Maria Mosconi
No relevant relationships to disclose
Michele Orditura
No relevant relationships to disclose
Stefania Bartolini
No relevant relationships to disclose
Valentina Arcangeli
No relevant relationships to disclose
Pierluigi Benedetti Panici
No relevant relationships to disclose
Carmela Pisano
No relevant relationships to disclose
Sabrina Chiara Cecere
No relevant relationships to disclose
Marilena Di Napoli
No relevant relationships to disclose
Francesco Raspagliesi
Consultant or Advisory Role - Roche
Vanda Salutari
No relevant relationships to disclose
Gennaro Daniele
No relevant relationships to disclose
Maria Carmela Piccirillo
No relevant relationships to disclose
Ciro Gallo
No relevant relationships to disclose
Francesco Perrone
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline